LCTX
AMEXLineage Cell Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.23-0.61 (-33.15%)
2026-03-052026-06-08
News · 26 weeks31-87%
2025-12-142026-06-07
Mix1790d
- SEC Filings8(47%)
- Other4(24%)
- Earnings2(12%)
- Insider1(6%)
- Leadership1(6%)
- Analyst1(6%)
Latest news
25 items- PRCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
- SECSEC Form 10-Q filed by Lineage Cell Therapeutics Inc.10-Q - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- SECLineage Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- PRLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatePositive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member Appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical
- PRLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 12, 2026, by
- PROpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features associated with recovery of photoreceptors Anatomical and functional improvements occur following a single administration of OpRegen cell therapy Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that 36-month results from patients enrolled in
- SECSEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- SECSEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Lineage Cell Therapeutics with a new price targetCanaccord Genuity initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $9.00
- PRLineage Announces Formation of Scientific Advisory BoardLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the formation of a Scientific Advisory Board (SAB) to provide strategic counsel and insights into the development of Lineage's novel cell transplant pipeline, built on the Company's proprietary cell differentiation and expansion platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). The founding member of the SAB is Joachim Fruebis, Ph.D., a recognized and established executive, who brings extensive experience across ophthalmology, n
- PRBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsAVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell Therapeutics, Inc. (NYSE:LCTX), Ocugen, Inc. (NASDAQ:OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Longeveron Inc. (NASDAQ:LGVN)Key Takeaways:Avaí Bio (OTCQB:AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1
- PRLineage Launches New Cell Therapy Program in Corneal Endothelial DiseaseNew Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline with the launch of COR1, a new corneal endothelial cell (CEnC) therapy program, in preclinical development for the treatment of corneal endothelial disease. Corneal endothelial disease is a progr
- SECSEC Form EFFECT filed by Lineage Cell Therapeutics Inc.EFFECT - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- INSIDERPresident and CEO Culley Brian M bought $24,375 worth of shares (15,000 units at $1.62), increasing direct ownership by 6% to 255,516 units (SEC Form 4)4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
- SECSEC Form S-3 filed by Lineage Cell Therapeutics Inc.S-3 - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- SECLineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- SECSEC Form 424B5 filed by Lineage Cell Therapeutics Inc.424B5 - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- INSIDERSEC Form 4 filed by President and CEO Culley Brian M4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Howe Jill Ann4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
- SECSEC Form 10-K filed by Lineage Cell Therapeutics Inc.10-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- SECLineage Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
- PRLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePositive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements Successfully Demonstrated the High-Scale Production Potential of Our Proprietary AlloSCOPE™ Manufacturing Platform Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Research Project in Type 1 Diabetes Treated First-Ever Chronic SCI Patient in OPC1 DOSED Device Safety Study Current Cash and Equivalents E
- PRLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the
- INSIDERGeneral Counsel and Secretary Samuel George A. Iii converted options into 6,075 shares and covered exercise/tax liability with 2,502 shares, increasing direct ownership by 13% to 31,063 units (SEC Form 4)4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
LCTX FAQ
6 questionsWhat does Lineage Cell Therapeutics Inc. do?
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic...Where does LCTX stock trade?
Lineage Cell Therapeutics Inc. (LCTX) is listed on AMEX.What sector and industry is LCTX in?
Lineage Cell Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about LCTX?
Lineage Cell Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $900.00 price target on 2026-04-28. Recent price targets range from $400.00 to $900.00.What companies are similar to LCTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare LCTX side-by-side with any of them on Quantisnow.How can I track LCTX on Quantisnow?
Quantisnow aggregates Lineage Cell Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LCTX to receive live email and push alerts on every new disclosure.